|
|
|
|
|
|
|
|
|
|
|
| ||||
Last Loaded on Web: Monday, April 01, 2013
Due to new restrictions recently imposed by the publisher, Informa, effective March 1, 2010 we are no longer able to offer their newsletter content except via site license. We regret any inconvenience this may cause. For information on alternative pharmaceutical industry news sources, please contact the Knowledge Center at customer@dialog.com.
The Pharmaceutical and Healthcare Industry News Database (PHIND) consists of two files: File 130 is the current material, updated daily, and contains the fulltext of all newsletter articles written in the last 25 to 30 days. File 129 is an archival database, and contains the fulltext of indexed articles from the full range of PJB newsletters dating back to 1980.
All publications follow a similar structure and contain sections on:
Pharmaceutical and Healthcare Industry News contains the fulltext of the following print publications:
EXPAND JN= online to see the codes for the various review issues. ONLINE PLUS editions of several of the newsletters are also available, providing additional articles not available in any printed newsletter. EXPAND JN= online to see the codes for the various ONLINE PLUS editions.
* Not available in print.
| ACRONYM | CATEGORY NAME |
|---|---|
| AGRIBUS | Food and Agriculture Industry |
| BIOBUS | Biosciences and Biotechnology Industry |
| DRUGECON | Pharmacoeconomics |
| HEALTHBU | Healthcare Industry News |
| NEWSDAIL | News, Current - Daily Updates |
| PHARMIND | Pharmaceutical Industry News |
| PHARMR | Pharmacology + RINGDOC-Files |
| PHIND | Pharmaceutical and Healthcare Industry |
| PJB | PJB Files |
|
PHIND is produced by Informa UK Ltd. Questions concerning file content should be directed to: Guy Morris 69-77 Paul Street London, EC2A 4LQ United Kingdom
|
For Dialog's Electronic Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.
Information in this database is copyrighted by Informa UK Ltd. All rights reserved. Informa UK Ltd. makes no warranties, express or implied, with respect to the accuracy, quality, validity, or completeness of this database or the information therein.
Informa UK Ltd. wishes to protect against infringement of its copyright and the conditions of use of its databases while allowing fair use of material supplied to its customers. Informa UK Ltd. requires payment of a fair and reasonable fee for reproduction and redistribution of information in its database(s) EXCEPT those activities listed below and those covered by the ERA(sm) service.
ALLOWED WITHOUT PERMISSION OR CHARGE
1. Online users of Informa UK Ltd. online databases may download data from those databases onto a personal computer (PC) or into their personal electronic mailbox and integrate that information into a computer file held on that PC.
2. Members of staff of the customer organisation at the customer location where the Informa UK Ltd. data is downloaded may examine the computer file holding that data, provided that this is done at the PC on which it is held.
3. Information downloaded onto a receiving PC may be moved to another PC located at the customer location provided the Informa UK Ltd. data is held on only one (1) PC and is accessible only at that PC.
4. Permission is granted to make one (1) electronic copy of the downloaded Informa UK Ltd. data for back-up security purposes to be used only if the first copy becomes unusable.
5. Online users may make occasional printed hardcopies of the downloaded Informa UK Ltd. data and this hardcopy may be examined by members of the customer organisation working at the customer location where the downloading took place. The hardcopy may be kept for reference in a central location such as a library at the customer location where downloading took place. Additional copying of this hardcopy is a breach of the copyright of Informa UK Ltd.
6.The downloaded Informa UK Ltd. data is restricted to employees of the customer and may not be exploited whether by way of sale, licence or to otherwise to any third party.
7. Informa UK Ltd. data may only be held in electronic form for a maximum period of 60 days from the date it is first downloaded and must then be deleted.
| DIALOG(R)File 130:PHIND(Daily & Current) | |
| (c) 2009 Informa UK Ltd. All rts. reserv. | |
| 0002000007 | |
| /TI | Bayer/J&J plan a complete response to the FDA on anticoagulant Xarelto |
| AU= | AUTHOR: Asher Mullard |
| JN=, PD=, SO= | Scrip, July 15, 2009 (20090715) |
| RT=, WD= | STORY TYPE: F WORD COUNT: 779 |
| AT= | CATEGORY: News |
| SC= | SECTION: R&D |
| /CO, CO= | COMPANIES: Bayer ; Johnson & Johnson |
| /TX | Bayer and Johnson & Johnson plan to submit a reply to the US |
| FDA's complete response letter on Xarelto (rivaroxaban), a | |
| potential blockbuster anticoagulant, in the fourth quarter of | |
| this year. | |
| Xarelto was developed by Bayer and will be marketed in the US, | |
| if approved, by Johnson & Johnson's Ortho-McNeil unit. J&J and | |
| the FDA will be meeting later this summer to define a path | |
| forward for the drug, and this meeting will determine the | |
| timeline for the submission of the complete response. | |
| Xarelto was filed in the US in July 2008 for the prevention of | |
| both deep vein thrombosis and pulmonary embolism in patients | |
| undergoing total hip or knee replacement surgery. Despite | |
| concerns over the drug's liver safety profile, it was given the | |
| nod by a cardiovascular and renal drugs committee earlier this | |
| year by a vote of 15 to two (scripnews.com, March 20th, 2009). | |
| The FDA issued a complete response letter for Xarelto in May, | |
| however. | |
| The FDA reportedly did not ask for new clinical or non-clinical | |
| studies to evaluate efficacy or safety, but did request | |
| additional data from completed and ongoing studies of the drug, | |
| as well as market surveillance from countries outside the US | |
| where it is already sold. These data will be used to assess the | |
| drug's risk-benefit profile. | |
| Xarelto is already approved in the EU and other markets for | |
| prevention of venous thromboembolism (VTE) after hip or knee | |
| replacement surgery. | |
| Xarelto acts as an anticoagulant by inhibiting Factor Xa, and it | |
| is in Phase III development for stroke prevention in atrial | |
| fibrillation patients and for acute coronary syndromes. Total | |
| peak sales of Xarelto have been estimated at (euro)2 billion. | |
| If approved in the US, Xarelto would compete with Lilly/Daiichi | |
| Sankyo's Effient (prasugrel), which was just approved by the FDA | |
| with a boxed warning (scripnews.com, July 13th, 2009). Other | |
| anticoagulants that could be fighting for a market share include | |
| experimental Factor Xa inhibitors like Bristol-Myers | |
| Squibb/Pfizer's apixaban, Astellas's YM150 and Daiichi-Sankyo's | |
| DU-176b, as well as Boehringer Ingelheim's thrombin inhibitor | |
| Pradaxa (dabigatran etexilate). Pradaxa is already approved in | |
| the EU for prevention of VTE after hip or knee replacement | |
| surgery but has not yet been filed in the US. | |
| Merck & Co has just acquired the rights to Portola's Factor Xa | |
| inhibitor betrixaban, which is in Phase II development for | |
| stroke prevention in atrial fibrillation (scripnews.com, July | |
| 10th, 2009). | |
| Scrip - Scrip World Pharmaceutical News - | |
| http://www.scripnews.com FILED July 15, 2009 | |
| Copyright Informa UK Limited 2009 | |
| SEARCH SUFFIX |
DISPLAY CODE |
FIELD NAME |
INDEXING |
SELECT EXAMPLES |
|---|---|---|---|---|
| None | None | All Basic Index Fields | Word | S PHASE(W)(II OR 2 OR TWO) |
| /CO | CO | Company Name4 | Word | S BAYER/CO |
| /TI | TI | Title | Word | S BAYER AND FDA/TI |
| /TX | TX | Text | Word | S (R()D()EXPENSES)/TX |
1 In File 129, the data in PD is the date of publication; in File 130, the data in PD is the date the record was written.
2 There is no source field for records that have not yet been published in print.
3 Not available in all records.
4 Available in many records from July 15, 2009 forward.
| SEARCH PREFIX |
DISPLAY CODE |
FIELD NAME |
INDEXING |
SELECT EXAMPLES |
|---|---|---|---|---|
| AA= | None | Supplier Accession Number | Phrase | |
| None | AN | DIALOG Accession Number | ||
| AT= | AT | Article Category4 | Phrase | S AT=EXPERT VIEW |
| AU= | AU | Author4 | Word | S AU=(ASHER(N)MULLARD) |
| CO= | CO | Company Name4 | Phrase | S CO="JOHNSON & JOHNSON" |
| IS= | IS | Issue Number3 | Phrase | S IS=305 |
| JN= | JN | Journal Name | Phrase | S JN=SCRIP |
| PD= | PD | Publication Date1 | Phrase | S PD=20090715 |
| PG= | PG | Page Number3 | Phrase | S PG=5 |
| PY= | PY | Publication Year | Phrase | S PY=2009 |
| RT= | RT | Story Type | Phrase | S RT=F |
| SC= | SC | Section3 | Phrase | S SC=R&D |
| SF= | None | Special Feature | Phrase | S SF=TABLE |
| SO= | SO | Journal, Issue, Page2 | Word | S SO=(AGROW AND 305 AND 5) |
| UD= | None | Update | Phrase | S UD=9999 |
| WD= | WD | Word Count | Phrase | S WD<1000 |
| SUFFIX | FIELD NAME | EXAMPLES |
|---|---|---|
| /NOTABLE | Records With No Tables | S S7/NOTABLE |
| /TABLE | Records Containing Tables | S S7/TABLE |
| SORTABLE FIELDS | EXAMPLES |
|---|---|
| AU, CO, JN, PD, PY, TI | SORT S5/ALL/JN PRINT S2/5/1/1-30/PD |
| RANK FIELDS | EXAMPLES |
|---|---|
| All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. | RANK AU S3 |
| User-defined formats may be specified using the display codes indicated in the Search Options tables. | TYPE S3/TI,SO/1-5 |
| NO. |
DIALOGWEB FORMAT |
RECORD CONTENT |
|---|---|---|
| 1 | -- | DIALOG Accession Number |
| 2 | -- | Title, Author, Source, Story Type, Word Count, Category, Section, and Company |
| 3 | Medium | Title, Author, Source, Story Type, Word Count, Category, Section, and Company |
| 4 | -- | Full Record with Tagged Fields |
| 5 | Long | Full Record |
| 6 | Free | Title and Word Count |
| 7 | -- | Title, Author, Source, Story Type, Word Count, Category, Section, and Company |
| 8 | Short | Title and Word Count |
| 9 | Full | Full Record |
| K | -- | KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats |
| FIELD NAME | EXAMPLES | ||
|---|---|---|---|
| DIALOG Accession Number | TYPE 00224358/5 DISPLAY 00223842/TI,SO PRINT 00223888/5 |
||
Rates For File: Pharmaceutical and Healthcare Industry News Database (PHIND) - Weekly - Subscribers[129]
Cost per DialUnit: $49.00
Cost per minute: $11.32
Rank Elements $0.00
ALERT (default) $24.00
ALERT (Monthly) * $39.00
ALERT (Biweekly/twice a month) * $31.00
ALERT (Weekly) $24.00
ALERT (Daily) * $12.25
ALERT (Calendar weekly) * $24.00
ALERT (Intraday) * $12.25
* = custom scheduled Alerts only
ALERT Number of included prints 0
Format Types Prints
1 $0.00 $0.00
2 $4.50 $4.50
3 $4.50 $4.50
4 $9.00 $9.00
5 $9.00 $9.00
6 $0.00 $0.00
7 $4.50 $4.50
8 $0.00 $0.00
9 $9.00 $9.00
KWIC95 $4.50 NA
KWIC96 $4.50 NA
REDIST/COPY Multiplier Table:
Range Multiplier
1-2 1.00
3-25 1.50
26-100 3.00
101-200 4.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
ARCHIVE Multiplier Table:
Range Multiplier
1-25 1.50
26-200 3.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
Rates For File: Pharmaceutical and Healthcare Industry News Database (PHIND) - Daily - Subscribers[130]
Cost per DialUnit: $54.00
Cost per minute: $12.45
Rank Elements $0.00
ALERT (default) $27.00
ALERT (Monthly) * $43.00
ALERT (Biweekly/twice a month) * $33.00
ALERT (Weekly) $27.00
ALERT (Daily) $13.50
ALERT (Calendar weekly) * $27.00
ALERT (Intraday) * $13.50
* = custom scheduled Alerts only
ALERT Number of included prints 0
Format Types Prints
1 $0.00 $0.00
2 $10.00 $10.00
3 $10.00 $10.00
4 $20.00 $20.00
5 $20.00 $20.00
6 $0.00 $0.00
7 $10.00 $10.00
8 $0.00 $0.00
9 $21.00 $21.00
KWIC95 $10.00 NA
KWIC96 $10.00 NA
REDIST/COPY Multiplier Table:
Range Multiplier
1-2 1.00
3-25 1.50
26-100 3.00
101-200 4.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
ARCHIVE Multiplier Table:
Range Multiplier
1-25 1.50
26-200 3.00
201-500 6.00
501-1000 8.00
1001 or more 10.00
